Stage B Heart Failure Treatment Recommendations

Definition and Diagnosis

The American College of Cardiology defines Stage B heart failure as structural heart disease without symptoms, corresponding to NYHA class I with no limitations on physical activity, which includes patients with left ventricular dysfunction (LVEF ≤40%), previous myocardial infarction, valvular heart disease, and left ventricular hypertrophy 1, 2

The American College of Cardiology recommends ACE inhibitors as the cornerstone of Stage B treatment for patients with LVEF ≤40%, with Class I, Level A evidence supporting their use to prevent symptomatic heart failure and reduce mortality 1
ACE inhibitors should be used in all patients with LVEF ≤40%, regardless of MI history, and for post-MI patients with LVEF ≤40%, ACE inhibitors specifically prevent symptomatic HF and reduce mortality 1
For patients intolerant to ACE inhibitors, ARBs should be used as an alternative, particularly in patients with recent MI and LVEF ≤40% 1
Evidence-based beta blockers should be used in all patients with LVEF ≤40% to prevent symptomatic heart failure, with Class I, Level B-R evidence supporting their use in post-MI patients with LVEF ≤40% to reduce mortality 1
Statins should be used in patients with recent or remote history of MI or acute coronary syndrome to prevent symptomatic heart failure and adverse cardiovascular events, with Class I, Level A evidence supporting their use 1

For patients at least 40 days post-MI with LVEF ≤30% and NYHA class I symptoms on optimal medical therapy, an ICD is recommended for primary prevention of sudden cardiac death, with the requirement of a reasonable expectation of meaningful survival >1 year 1

Thiazolidinediones should not be used in patients with LVEF <50% as they increase the risk of heart failure and hospitalizations 1
Nondihydropyridine calcium channel blockers (diltiazem, verapamil) with negative inotropic effects should be avoided in patients with LVEF <50% as they may be harmful 1

When starting ACE inhibitors, review and adjust diuretic and vasodilator doses, avoid excessive diuresis before treatment initiation, consider evening dosing when supine to minimize hypotensive effects, and monitor renal function and potassium closely 2, 3
Monitor blood urea nitrogen, creatinine, potassium, and sodium when adjusting medications affecting the renin-angiotensin-aldosterone system, blood pressure and heart rate with each dose adjustment, and symptoms and functional capacity 2, 3

The primary goals in Stage B are to prevent progression to symptomatic heart failure (Stage C), reduce mortality risk, prevent adverse ventricular remodeling, and optimize cardiovascular risk factors 2, 3

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitively classify Stage B heart failure as heart failure, specifically defined as structural heart disease without current or previous symptoms or signs of heart failure 4
Stage B heart failure represents established structural heart disease that is part of the heart failure disease continuum, even though patients remain asymptomatic, and should be coded as heart failure 4

The ACC/AHA staging system explicitly recognizes Stage B as part of the heart failure spectrum, not merely a "risk state", and patients with structural heart disease have substantially elevated mortality risk compared to those without structural disease 4
The presence of structural heart disease in Stage B patients qualifies them for heart failure-specific management, including evidence-based therapies such as ACE inhibitors/ARBs and beta-blockers to prevent progression to symptomatic heart failure 4